ASCO 2026: Updated Data Show Extended Survival With Amivantamab-Lazertinib in Atypical EGFR-Mutant Lung Cancer

Patients with non-small cell lung cancer (NSCLC) driven by "atypical" EGFR mutations have historically had worse outcomes than those with the more common, classical EGFR mutations. Updated data from Cohort C of the phase 1/Ib CHRYSALIS-2 study, presented at the 2026 ASCO Annual Meeting, suggest that gap may be narrowing.

Among 49 treatment-naive patients with atypical EGFR-mutated advanced NSCLC who received first-line amivantamab plus lazertinib, researchers reported a median overall survival of 41.0 months. The combination's safety profile was consistent with prior reports from the same study, with no new safety signals identified as follow-up lengthened.

The result builds on the phase 3 MARIPOSA trial, which previously demonstrated a statistically significant overall survival benefit for the same amivantamab-lazertinib combination over osimertinib alone in patients with classical EGFR mutations. Together, the two datasets support a broader role for the combination across a wider range of EGFR-mutant lung cancer subtypes than osimertinib monotherapy has historically covered.

EGFR remains one of the most extensively studied "driver mutation" categories in lung cancer research — you can see how many active trials are currently testing EGFR-directed approaches, along with five other major treatment categories, on our live Research Progress Tracker.